Correspondence 0001213900-24-002573 from IceCure Medical Ltd. (ICCM)
IceCure Medical Ltd.
Date: Jan. 10, 2024 · CIK: 0001584371 · Accession: 0001213900-24-002573
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-40753
Referenced dates: January 9, 2024
Letter
Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Re: IceCure Medical Ltd. Supplemental Response dated October 13, 2023 Annual Report on Form 20-F filed March 29, 2023 File No. 001-40753
Dear Sir and Madam:
The purpose of this letter is to respond to the comment letter dated January 9, 2024 received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission regarding the above-mentioned Annual Report on Form 20-F (“Form 20-F”). For your convenience, your original comment appears in bold text, followed by our response.
Supplemental Response Dated October 13, 2023, regarding Annual Report on Form 20-F filed March 29, 2023
General
1. We note in your response that one of the members of the board of directors of the Company is a Chinese citizen and another holds British citizenship and citizenship of the Hong Kong Special Administrative Region of the People’s Republic of China. In future filings, to the extent that one or more of your officers and/or directors are located in China or Hong Kong, please create a separate Enforceability of Civil Liabilities section for the discussion of the enforcement risks related to civil liabilities due to your officers and directors being located in China or Hong Kong. Please identify each officer and/or director located in China or Hong Kong and disclose that it will be more difficult to enforce liabilities and enforce judgments on those individuals. For example, discuss more specifically the limitations on investors being able to effect service of process and enforce civil liabilities in China, lack of reciprocity and treaties, and cost and time constraints. Also, please disclose these risks in a separate risk factor, which should contain disclosures consistent with the separate section, and include the risk in your summary risk factor disclosure.
Response: We acknowledge the Staff’s comment and will include disclosure and a risk factor regarding the enforceability of civil liabilities with regards to members of the board of directors who are located in China or Hong Kong in future filings.
If you have any questions or require additional information regarding this letter, please do not hesitate to contact Eric Victorson at (212) 660-3092 or Oded Har-Even at (212) 660-5002, each of Sullivan & Worcester LLP.
Sincerely,
IceCure Medical Ltd.
Show Raw Text
CORRESP
1
filename1.htm
IceCure Medical Ltd.
7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
January 10, 2024
Via EDGAR
Benjamin Richie
Abby Adams
Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, NE
Washington, DC 20549
Re:
IceCure Medical Ltd.
Supplemental Response dated October 13, 2023
Annual Report on Form 20-F filed March 29, 2023
File No. 001-40753
Dear Sir and Madam:
The purpose of this letter is to respond to the
comment letter dated January 9, 2024 received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission
regarding the above-mentioned Annual Report on Form 20-F (“Form 20-F”). For your convenience, your original comment appears
in bold text, followed by our response.
Supplemental Response Dated October 13, 2023, regarding Annual
Report on Form 20-F filed March 29, 2023
General
1. We note in your response that one of the members of the board of directors of the Company is a Chinese
citizen and another holds British citizenship and citizenship of the Hong Kong Special Administrative Region of the People’s Republic
of China. In future filings, to the extent that one or more of your officers and/or directors are located in China or Hong Kong, please
create a separate Enforceability of Civil Liabilities section for the discussion of the enforcement risks related to civil liabilities
due to your officers and directors being located in China or Hong Kong. Please identify each officer and/or director located in China
or Hong Kong and disclose that it will be more difficult to enforce liabilities and enforce judgments on those individuals. For example,
discuss more specifically the limitations on investors being able to effect service of process and enforce civil liabilities in China,
lack of reciprocity and treaties, and cost and time constraints. Also, please disclose these risks in a separate risk factor, which should
contain disclosures consistent with the separate section, and include the risk in your summary risk factor disclosure.
Response: We acknowledge the
Staff’s comment and will include disclosure and a risk factor regarding the enforceability of civil liabilities with regards to
members of the board of directors who are located in China or Hong Kong in future filings.
If you have any questions or require additional
information regarding this letter, please do not hesitate to contact Eric Victorson at (212) 660-3092 or Oded Har-Even at (212) 660-5002,
each of Sullivan & Worcester LLP.
Sincerely,
IceCure Medical Ltd.
By:
/s/ Eyal Shamir
Eyal Shamir
Chief Executive Officer